158 related articles for article (PubMed ID: 3027404)
21. Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23.
Wang F; Gregory CD; Rowe M; Rickinson AB; Wang D; Birkenbach M; Kikutani H; Kishimoto T; Kieff E
Proc Natl Acad Sci U S A; 1987 May; 84(10):3452-6. PubMed ID: 3033649
[TBL] [Abstract][Full Text] [Related]
22. Infection of human thymocytes by Epstein-Barr virus.
Watry D; Hedrick JA; Siervo S; Rhodes G; Lamberti JJ; Lambris JD; Tsoukas CD
J Exp Med; 1991 Apr; 173(4):971-80. PubMed ID: 1706754
[TBL] [Abstract][Full Text] [Related]
23. Establishment of a human B cell line that proliferates in response to B cell growth factor.
Abe H; Rossio JL; Ruscetti FW; Matsushima K; Oppenheim JJ
J Immunol Methods; 1986 Jun; 90(1):111-23. PubMed ID: 2423613
[TBL] [Abstract][Full Text] [Related]
24. Determination of the role for CD21 during Epstein-Barr virus infection of B-lymphoblastoid cells.
Martin DR; Marlowe RL; Ahearn JM
J Virol; 1994 Aug; 68(8):4716-26. PubMed ID: 7913508
[TBL] [Abstract][Full Text] [Related]
25. Identification of three gp350/220 regions involved in Epstein-Barr virus invasion of host cells.
Urquiza M; Lopez R; Patiño H; Rosas JE; Patarroyo ME
J Biol Chem; 2005 Oct; 280(42):35598-605. PubMed ID: 16087675
[TBL] [Abstract][Full Text] [Related]
26. Autocrine growth of human B lymphocytes: maintained response to autostimulatory factors is the special feature of immortalization by Epstein-Barr virus--a hypothesis.
Gordon J; Guy G; Walker L; Nathan P; Exley R; Clemens M
Med Oncol Tumor Pharmacother; 1986; 3(3-4):269-73. PubMed ID: 3027466
[TBL] [Abstract][Full Text] [Related]
27. Kinetics of interleukin-4 induction and interferon-gamma inhibition of IgE secretion by Epstein-Barr virus-infected human peripheral blood B cells.
Thyphronitis G; Banchereau J; Heusser C; Tsokos GC; Levine AD; Finkelman FD
Cell Immunol; 1991 Apr; 133(2):408-19. PubMed ID: 1849800
[TBL] [Abstract][Full Text] [Related]
28. Interleukin 15-mediated induction of cytotoxic effector cells capable of eliminating Epstein-Barr virus-transformed/immortalized lymphocytes in culture.
Sharif-Askari E; Fawaz LM; Tran P; Ahmad A; Menezes J
J Natl Cancer Inst; 2001 Nov; 93(22):1724-32. PubMed ID: 11717333
[TBL] [Abstract][Full Text] [Related]
29. Effect of cytokines on proliferation of Epstein Barr virus-transformed B lymphocytes.
Richter W; Eiermann TH; Scherbaum WA
Hybridoma; 1990 Feb; 9(1):1-8. PubMed ID: 2155870
[TBL] [Abstract][Full Text] [Related]
30. Epstein-Barr virus receptor expression on human CD8+ (cytotoxic/suppressor) T lymphocytes.
Sauvageau G; Stocco R; Kasparian S; Menezes J
J Gen Virol; 1990 Feb; 71 ( Pt 2)():379-86. PubMed ID: 2155291
[TBL] [Abstract][Full Text] [Related]
31. Induction of latent membrane protein expression in in vitro Epstein-Barr virus-infected leukaemic B lymphocytes by interleukin 4 and antibodies to CD40.
Crawford DH; Thomas JA; Gregory CD; Catovsky D; Chaggar K
Leukemia; 1995 May; 9(5):747-53. PubMed ID: 7539512
[TBL] [Abstract][Full Text] [Related]
32. Epstein-Barr Virus and its glycoprotein-350 upregulate IL-6 in human B-lymphocytes via CD21, involving activation of NF-kappaB and different signaling pathways.
D'Addario M; Libermann TA; Xu J; Ahmad A; Menezes J
J Mol Biol; 2001 May; 308(3):501-14. PubMed ID: 11327783
[TBL] [Abstract][Full Text] [Related]
33. Characterization of the EBV/C3d receptor on the human Jurkat T cell line: evidence for a novel transcript.
Sinha SK; Todd SC; Hedrick JA; Speiser CL; Lambris JD; Tsoukas CD
J Immunol; 1993 Jun; 150(12):5311-20. PubMed ID: 8390533
[TBL] [Abstract][Full Text] [Related]
34. Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis.
Tanner J; Weis J; Fearon D; Whang Y; Kieff E
Cell; 1987 Jul; 50(2):203-13. PubMed ID: 3036369
[TBL] [Abstract][Full Text] [Related]
35. Differences in Epstein-Barr virus (EBV) receptors expression on various human lymphoid targets and their significance to EBV-cell interaction.
Stocco R; Sauvageau G; Menezes J
Virus Res; 1988 Oct; 11(3):209-25. PubMed ID: 2848382
[TBL] [Abstract][Full Text] [Related]
36. Determination of the structural basis for selective binding of Epstein-Barr virus to human complement receptor type 2.
Martin DR; Yuryev A; Kalli KR; Fearon DT; Ahearn JM
J Exp Med; 1991 Dec; 174(6):1299-311. PubMed ID: 1660522
[TBL] [Abstract][Full Text] [Related]
37. IgE secretion by Epstein-Barr virus-infected purified human B lymphocytes is stimulated by interleukin 4 and suppressed by interferon gamma.
Thyphronitis G; Tsokos GC; June CH; Levine AD; Finkelman FD
Proc Natl Acad Sci U S A; 1989 Jul; 86(14):5580-4. PubMed ID: 2546158
[TBL] [Abstract][Full Text] [Related]
38. Identification of a major 50-kDa molecular weight human B-cell growth factor with Tac antigen-inducing activity on B cells.
Kawano M; Matsushima K; Oppenheim JJ
Cell Immunol; 1987 Aug; 108(1):132-49. PubMed ID: 3111722
[TBL] [Abstract][Full Text] [Related]
39. Effect of cell-derived growth factors and cytokines on the clonal outgrowth of EBV-infected B cells and established lymphoblastoid cell lines.
Ifversen P; Zhang XM; Ohlin M; Zeuthen J; Borrebaeck CA
Hum Antibodies Hybridomas; 1993 Jul; 4(3):115-23. PubMed ID: 8395232
[TBL] [Abstract][Full Text] [Related]
40. Model for studying virus attachment: identification and quantitation of Epstein-Barr virus-binding cells by using biotinylated virus in flow cytometry.
Inghirami G; Nakamura M; Balow JE; Notkins AL; Casali P
J Virol; 1988 Jul; 62(7):2453-63. PubMed ID: 2836625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
